COSMOS Pharmaceutical Corporation (3349) AI Stock Analysis

• Market Cap: ¥702.23B
• Dividend Yield: 0.74%
• Average Volume (3M): 345.77K
• Price to Earnings (P/E): 23.8
• Beta (1Y): -0.28
• Revenue Growth: 6.96%
• EPS Growth: -3.96%
• Country: JP
• Employees: 5,512
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 99.86
• Shares Outstanding: 80,001,600
• 10 Day Avg. Volume: 328,970
• 30 Day Avg. Volume: 345,766
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥9,400.00
• Price Target Upside: 6.55% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

• Rating: 70 Neutral
• Price Target: ¥9,629.00 ▲(9.15%Upside)

The most significant factor is the company's strong financial performance, underscored by robust revenue growth and a stable balance sheet. Technical analysis also supports a positive outlook, though mixed signals may indicate caution. Valuation metrics suggest the stock is fairly valued, but the low dividend yield is a secondary consideration.

COSMOS Pharmaceutical Corporation Business Overview & Revenue Model

Company Description

COSMOS Pharmaceutical Corporation (3349) is a leading company in the pharmaceutical retail sector, operating a chain of drugstores across Japan. The company is renowned for offering a wide range of healthcare products, including prescription medications, over-the-counter drugs, health supplements, and personal care items. COSMOS focuses on providing high-quality products and services to support the health and well-being of its customers.

How the Company Makes Money

COSMOS Pharmaceutical Corporation generates revenue primarily through its extensive network of drugstores, where it sells a variety of pharmaceutical and healthcare products. The company's key revenue streams include the sale of prescription medications, over-the-counter drugs, and health-related goods. Additionally, COSMOS benefits from its strategic locations and customer loyalty programs, which drive consistent foot traffic and repeat purchases. Partnerships with pharmaceutical manufacturers and efficient supply chain management also play a crucial role in maintaining competitive pricing and ensuring product availability, further contributing to the company's financial performance.

COSMOS Pharmaceutical Corporation Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
964.99B	827.70B	755.41B	726.42B	684.40B
	Gross Profit
188.31B	168.72B	151.45B	145.11B	134.98B
	EBIT
31.50B	30.13B	29.80B	33.15B	29.09B
	EBITDA
53.74B	47.50B	44.91B	46.93B	42.66B
	Net Income Common Stockholders
24.45B	23.80B	23.16B	27.16B	21.43B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
52.30B	45.93B	37.36B	55.11B	52.12B
	Total Assets
476.55B	420.97B	363.05B	341.32B	320.28B
	Total Debt
34.06B	18.20B	9.41B	10.44B	12.12B
	Net Debt
-18.24B	-27.73B	-27.95B	-44.66B	-40.00B
	Total Liabilities
245.10B	209.90B	172.54B	170.74B	174.61B
	Stockholders Equity
231.44B	211.07B	190.51B	170.58B	145.68B
Cash Flow		Free Cash Flow
-635.00M	7.80B	-11.30B	1.81B	39.51B
	Operating Cash Flow
55.17B	54.43B	32.19B	27.88B	65.46B
	Investing Cash Flow
-57.33B	-49.11B	-43.72B	-19.38B	-26.96B
	Financing Cash Flow
8.53B	3.25B	-6.22B	-5.51B	-5.41B

COSMOS Pharmaceutical Corporation Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 8822.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3349, the sentiment is Neutral. The current price of 8822 is below the 20-day moving average (MA) of 8942.61, above the 50-day MA of 8575.38, and above the 200-day MA of 7483.40, indicating a neutral trend. The MACD of 44.73 indicates Positive momentum. The RSI at 49.66 is Neutral, neither overbought nor oversold. The STOCH value of 18.20 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:3349.

COSMOS Pharmaceutical Corporation Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3549	78 Outperform	¥368.26B	19.29		0.40%	13.86%	98.99%
7649	74 Outperform	$594.26B	22.21	10.45%	1.04%	17.94%	18.31%
3141	74 Outperform	¥534.57B	35.49		1.40%	5.56%	-43.50%
3391	71 Outperform	$554.48B	25.41	4.93%	3.26%	4.63%	-47.30%
9989	70 Outperform	$516.10B	16.79	11.61%	2.83%	6.66%	5.56%
3349	70 Neutral	¥702.23B	23.75		0.74%	6.96%	-3.96%
Sector *	54 Neutral	$5.31B	3.28	-45.10%	2.80%	16.76%	0.02%

COSMOS Pharmaceutical Corporation Corporate Events

COSMOS Pharmaceutical Reports Strong Financial Growth for Nine-Month Period

COSMOS Pharmaceutical Corporation reported a significant increase in its financial performance for the nine months ending February 28, 2025, with net sales rising by 5.2% and operating profit increasing by 33.2% compared to the previous period. The company’s improved financial results reflect a robust operational strategy, enhancing its market position and potentially benefiting stakeholders through increased profitability and shareholder value.